Ranbaxy news from FiercePharma
NewsRanbaxy probe includes AIDS relief meds
Ranbaxy can't be happy. The Indian company's stock is way down for the second day in a row, on news that the U.S. investigation into its operations includes allegations that it made weak or Read more...
Feds say Ranbaxy faked data
Ranbaxy Laboratories found itself in hot water with the feds late last week, just days after announcing its merger deal with Japanese giant Daiichi Sankyo. U.S. investigators and the FDA apparently Read more...
M&A menu: India's top 10 drugmakers
SPOTLIGHT: India's top 10 drugmakersAs soon as Ranbaxy's founding Singh family agreed to sell out to Japan's Daiichi Sankyo, the Indian press started speculating about which pharma firm might be next Read more...
Pfizer, Ranbaxy settle Lipitor patent dispute
Pfizer and Ranbaxy have come to an agreement that will end most of their five-year battle over the generic production of Lipitor, the world's best-selling drug. Ranbaxy will have a license to sell Read more...
Indians ask Ranbaxy CEO who's next
In the investment world, the proposed Daiichi Sankyo-Ranbaxy Laboratories merger is just another big deal. But in India, it's taken on symbolic significance. The family-controlled company Read more...
Will Pfizer counterbid for Ranbaxy?
We could have a takeover battle on our hands, folks. Pfizer is reportedly mulling a hostile bid for Ranbaxy, which just inked a Read more...
Daiichi buys $4.6B stake in Ranbaxy
These days, emerging markets and generic drugs are hot, and Japan's Daiichi Sankyo just landed a deal that capitalizes on both trends. The company is shelling out a hefty $4.6 billion for a majority Read more...
ALSO NOTED: Pfizer gets new cancer team to advance key drugs; Bayer clearing Trasylol off U.S. market;
> With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to lead the company to the promised land of new cancer therapies. Read more...
ALSO NOTED: Forest takes charge on Azor split; GSK launches Tykerb-Herceptin trials;
> Forest Laboratories will take a $44.1 million charge on termination of its deal to co-promote the hypertension drug Azor with Daiichi Sankyo. Read more...
Office upholds Pfizer's Lipitor patent
Pfizer is breathing a big sigh of relief. The U.S. Patent & Trademark Office has said it will confirm the drugmaker's basic patent on the blockbuster Lipitor drug. The office had been Read more...
| Press ReleasesPRESS RELEASE: Ranbaxy's Q3 PAT Increases 48% Ranbaxy's Q3 PAT Increases 48% GLOBAL SALES AT USD 406 MN, UP BY 15% IN PRINCIPLE BOARD APPROVAL FOR R&D DEMERGER FOR DRUG DISCOVERY RESEARCH Gurgaon, Haryana, India - October 18, 2007 The Read more... PRESS RELEASE: Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP Ranbaxy One of Few Companies to Offer Both Suspension and Tablet Forms PRINCETON, N.J., Oct. 2 -- Read more... PRESS RELEASE: Canadian Court Favors Ranbaxy, Dismisses Pfizer's Application on Atrovastatin Patent CANADIAN FEDERAL COURT FAVOURS RANBAXY DISMISSES PFIZER'S APPLICATION ON ATORVASTATIN PATENT CA 2,220,455 Gurgaon, Haryana, India, Princeton, New Jersey, USA - September 13, 2007 Ranbaxy Read more... PRESS RELEASE: Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis Ranbaxy will benefit from the 180 day shared exclusivity on the product PRINCETON, N.J. -- Read more... |
Get more Ranbaxy coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets